BioAge Labs (BIOA) Competitors $5.50 +0.15 (+2.80%) Closing price 04:00 PM EasternExtended Trading$5.50 0.00 (-0.09%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BIOA vs. GYRE, PRME, IOVA, RZLT, NRIX, DAWN, AKBA, OLMA, TYRA, and TERNShould you be buying BioAge Labs stock or one of its competitors? The main competitors of BioAge Labs include Gyre Therapeutics (GYRE), Prime Medicine (PRME), Iovance Biotherapeutics (IOVA), Rezolute (RZLT), Nurix Therapeutics (NRIX), Day One Biopharmaceuticals (DAWN), Akebia Therapeutics (AKBA), Olema Pharmaceuticals (OLMA), Tyra Biosciences (TYRA), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry. BioAge Labs vs. Its Competitors Gyre Therapeutics Prime Medicine Iovance Biotherapeutics Rezolute Nurix Therapeutics Day One Biopharmaceuticals Akebia Therapeutics Olema Pharmaceuticals Tyra Biosciences Terns Pharmaceuticals Gyre Therapeutics (NASDAQ:GYRE) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability. Do institutionals & insiders hold more shares of GYRE or BIOA? 24.0% of Gyre Therapeutics shares are held by institutional investors. 10.0% of Gyre Therapeutics shares are held by insiders. Comparatively, 20.8% of BioAge Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend GYRE or BIOA? Gyre Therapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 102.62%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Gyre Therapeutics is more favorable than BioAge Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50BioAge Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is GYRE or BIOA more profitable? Gyre Therapeutics has a net margin of 4.08% compared to BioAge Labs' net margin of 0.00%. Gyre Therapeutics' return on equity of 7.67% beat BioAge Labs' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics4.08% 7.67% 6.19% BioAge Labs N/A -25.39%-23.22% Does the media prefer GYRE or BIOA? In the previous week, Gyre Therapeutics had 3 more articles in the media than BioAge Labs. MarketBeat recorded 6 mentions for Gyre Therapeutics and 3 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.83 beat Gyre Therapeutics' score of 0.59 indicating that BioAge Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, GYRE or BIOA? Gyre Therapeutics has higher revenue and earnings than BioAge Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$102.19M7.91$12.09M$0.01839.00BioAge Labs$3.86M51.04-$71.11MN/AN/A SummaryGyre Therapeutics beats BioAge Labs on 10 of the 13 factors compared between the two stocks. Get BioAge Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOA vs. The Competition Export to ExcelMetricBioAge LabsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$197.18M$1.00B$2.52B$10.45BDividend YieldN/A4.84%2.51%4.79%P/E RatioN/A1.2826.2227.12Price / Sales51.0430.96121.64188.70Price / CashN/A17.6445.0330.17Price / Book0.617.5438.236.69Net Income-$71.11M-$7.59M$6.97M$276.03M7 Day Performance-2.31%-1.51%-1.50%-1.13%1 Month Performance14.58%18.97%0.54%6.48%1 Year PerformanceN/A-9.02%67.91%34.34% BioAge Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIOABioAge Labs0.1818 of 5 stars$5.50+2.8%N/AN/A$197.18M$3.86M0.00N/AGYREGyre Therapeutics1.5551 of 5 stars$7.96+11.3%$17.00+113.6%-39.7%$766.65M$105.76M796.8040Analyst ForecastHigh Trading VolumePRMEPrime Medicine3.4823 of 5 stars$5.68-8.8%$8.92+57.0%+56.0%$764.38M$4.96M-2.77234Gap UpHigh Trading VolumeIOVAIovance Biotherapeutics4.5198 of 5 stars$2.10-4.1%$11.90+466.7%-78.4%$759.89M$164.07M-1.71500Gap UpRZLTRezolute2.9352 of 5 stars$8.27-6.3%$14.50+75.3%+76.0%$751.15MN/A-8.5340NRIXNurix Therapeutics1.719 of 5 stars$9.76-10.1%$28.14+188.3%-58.7%$746.14M$54.55M-3.29300Earnings ReportAnalyst ForecastDAWNDay One Biopharmaceuticals2.8739 of 5 stars$7.24-2.8%$25.29+249.5%-47.9%$741.61M$131.16M-7.6260AKBAAkebia Therapeutics3.4632 of 5 stars$2.75-4.8%$6.75+145.5%+108.3%$729.15M$160.18M-16.18430OLMAOlema Pharmaceuticals2.5189 of 5 stars$10.57-1.0%$23.33+120.8%-10.0%$725.46MN/A-5.3470TYRATyra Biosciences2.0074 of 5 stars$13.52-2.2%$31.86+135.6%-38.4%$720.58MN/A-7.6020TERNTerns Pharmaceuticals3.6831 of 5 stars$8.15-4.1%$15.49+90.0%+6.3%$713.21MN/A-7.8440 Related Companies and Tools Related Companies GYRE Alternatives PRME Alternatives IOVA Alternatives RZLT Alternatives NRIX Alternatives DAWN Alternatives AKBA Alternatives OLMA Alternatives TYRA Alternatives TERN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIOA) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAge Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAge Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
